File Download
Links for fulltext
(May Require Subscription)
- Publisher Website: 10.3389/fonc.2019.00081
- Scopus: eid_2-s2.0-85063263950
- PMID: 30873380
- WOS: WOS:000459690900001
- Find via
Supplementary
- Citations:
- Appears in Collections:
Article: Viral-Targeted Strategies Against EBV-Associated Lymphoproliferative Diseases
Title | Viral-Targeted Strategies Against EBV-Associated Lymphoproliferative Diseases |
---|---|
Authors | |
Keywords | Epstein-Barr virus lymphoproliferative diseases viral-targeted strategies EBV latency lytic cycle reactivation |
Issue Date | 2019 |
Publisher | Frontiers Research Foundation. The Journal's web site is located at http://www.frontiersin.org/oncology |
Citation | Frontiers in Oncology, 2019, v. 9, p. article no. 81 How to Cite? |
Abstract | Epstein-Barr virus (EBV) is strongly associated with a spectrum of EBV-associated lymphoproliferative diseases (EBV-LPDs) ranging from post-transplant lymphoproliferative disorder, B cell lymphomas (e.g., endemic Burkitt lymphoma, Hodgkin lymphoma, and diffuse large B cell lymphoma) to NK or T cell lymphoma (e.g., nasal NK/T-cell lymphoma). The virus expresses a number of latent viral proteins which are able to manipulate cell cycle and cell death processes to promote survival of the tumor cells. Several FDA-approved drugs or novel compounds have been shown to induce killing of some of the EBV-LPDs by inhibiting the function of latent viral proteins or activating the viral lytic cycle from latency. Here, we aim to provide an overview on the mechanisms by which EBV employs to drive the pathogenesis of various EBV-LPDs and to maintain the survival of the tumor cells followed by a discussion on the development of viral-targeted strategies based on the understanding of the patho-mechanisms. |
Persistent Identifier | http://hdl.handle.net/10722/290630 |
ISSN | 2023 Impact Factor: 3.5 2023 SCImago Journal Rankings: 1.066 |
PubMed Central ID | |
ISI Accession Number ID |
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Hui, KF | - |
dc.contributor.author | YIU, SPT | - |
dc.contributor.author | TAM, KP | - |
dc.contributor.author | Chiang, AKS | - |
dc.date.accessioned | 2020-11-02T05:44:55Z | - |
dc.date.available | 2020-11-02T05:44:55Z | - |
dc.date.issued | 2019 | - |
dc.identifier.citation | Frontiers in Oncology, 2019, v. 9, p. article no. 81 | - |
dc.identifier.issn | 2234-943X | - |
dc.identifier.uri | http://hdl.handle.net/10722/290630 | - |
dc.description.abstract | Epstein-Barr virus (EBV) is strongly associated with a spectrum of EBV-associated lymphoproliferative diseases (EBV-LPDs) ranging from post-transplant lymphoproliferative disorder, B cell lymphomas (e.g., endemic Burkitt lymphoma, Hodgkin lymphoma, and diffuse large B cell lymphoma) to NK or T cell lymphoma (e.g., nasal NK/T-cell lymphoma). The virus expresses a number of latent viral proteins which are able to manipulate cell cycle and cell death processes to promote survival of the tumor cells. Several FDA-approved drugs or novel compounds have been shown to induce killing of some of the EBV-LPDs by inhibiting the function of latent viral proteins or activating the viral lytic cycle from latency. Here, we aim to provide an overview on the mechanisms by which EBV employs to drive the pathogenesis of various EBV-LPDs and to maintain the survival of the tumor cells followed by a discussion on the development of viral-targeted strategies based on the understanding of the patho-mechanisms. | - |
dc.language | eng | - |
dc.publisher | Frontiers Research Foundation. The Journal's web site is located at http://www.frontiersin.org/oncology | - |
dc.relation.ispartof | Frontiers in Oncology | - |
dc.rights | This Document is Protected by copyright and was first published by Frontiers. All rights reserved. It is reproduced with permission. | - |
dc.rights | This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License. | - |
dc.subject | Epstein-Barr virus | - |
dc.subject | lymphoproliferative diseases | - |
dc.subject | viral-targeted strategies | - |
dc.subject | EBV latency | - |
dc.subject | lytic cycle reactivation | - |
dc.title | Viral-Targeted Strategies Against EBV-Associated Lymphoproliferative Diseases | - |
dc.type | Article | - |
dc.identifier.email | Chiang, AKS: chiangak@hku.hk | - |
dc.identifier.authority | Chiang, AKS=rp00403 | - |
dc.description.nature | published_or_final_version | - |
dc.identifier.doi | 10.3389/fonc.2019.00081 | - |
dc.identifier.pmid | 30873380 | - |
dc.identifier.pmcid | PMC6400835 | - |
dc.identifier.scopus | eid_2-s2.0-85063263950 | - |
dc.identifier.hkuros | 317765 | - |
dc.identifier.volume | 9 | - |
dc.identifier.spage | article no. 81 | - |
dc.identifier.epage | article no. 81 | - |
dc.identifier.isi | WOS:000459690900001 | - |
dc.publisher.place | Switzerland | - |
dc.identifier.issnl | 2234-943X | - |